Cultivating novel compounds to fight bacterial infections & cancer

Formed in 2012 Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of a novel vaccine to prevent bacterial infections, as well as medicines for treating cancers and lung infections associated with cystic fibrosis.

Our approach

Beginning treatment with plant-based technologies

Since 1999, we have been advancing one of the most cutting-edge purification and characterization technologies to enable the discovery of novel compounds from plants. Our partnership with the Missouri Botanical Garden in Saint Louis, Missouri allowed us to apply our technologies to a myriad of plants from around the world.

These research efforts led us to discover dozens of new chemical scaffolds, inspiring the initiation of the vaccines program and enabling us to launch new programs to treat cancer and bacterial infections.

We are highly committed to the development of vaccines to prevent bacterial infections and solve the worldwide antibiotic resistance crisis by reducing dependence on antibiotics.

The CDC's stance on antimicrobial resistance

Source: Antimicrobial Resistance Challenge, 2018 and 2019; CMS Condition of Participation, 2019; Vaccines recommended to the CDC and HHS by the physicians of the Advisory Committee on Immunization Practices are covered by insurers; Lob et al. Diagn Microbiol Infect Dis 2016, 85, 459-465; Critchley et al. PLOS ONE, 2019, 14(12): e0220265. Jernigan et al. N Engl J Med. 2020;382(14):1309-1319.

In 2018 and 2019, the CDC and the United States Department of Health and Human Services (HHS) led the Antimicrobial Resistance Challenge to implement strategies to reduce the development of antibiotic resistance.

This Challenge received commitments from more than 300 healthcare systems, health insurance companies, medical professionals, and government health organizations. One of these commitments was to invest in the development and commercialization of vaccines.

The CDC supports the prevention of bacterial infections via immunizations. The CDC’s Core Elements of Hospital Antibiotic Stewardship program has encouraged hospitals to implement initiatives to help reduce antibiotic prescriptions in outpatient settings.

Today, the CDC continues to promote antimicrobial stewardship programs to reduce the use of antibiotics; however, UTI cases caused by multidrug-resistant extended-spectrum beta-lactamase Escherichia coli continue to rise because of the overuse of antibiotics.

The Advisory Committee on Immunization Practices (ACIP), which operates at the CDC to make recommendations regarding the adoption of new vaccines, considers the safety and effectiveness of every vaccine and the severity of the disease. Vaccine recommendations from the ACIP are generally adopted.

Advancing multiple pipeline programs

Our product pipeline includes programs that are designed to combat antimicrobial resistance and target bacterial infections, as well as broad anti-cancer therapeutics.

Our candidates and discovery platforms

  • SEQ-400 for Recurrent UTIs
  • SEQ-1274 and analogs for Ovarian/Other Cancers
  • A novel analog platform for Lung Infections in Cystic Fibrosis
View our pipeline

A robust patent portfolio

We solely own our patents that contain composition and method of use claims covering our vaccine and adjuvant.

  • 12 issued U.S. patents1

1. U.S. Patent Numbers 9,017,698; 9,149,521; 9,149,522; 9,415,097; 9,415,101; 9,492,522; 9,504,743; 9,878,037; 10,058,608; 10,137,192; 10,525,128 and 11,110,169

Backed by pharmaceutical leaders

Committed to improving patients' quality of life

Our esteemed leadership team possesses over 100 years of combined experience in pharmaceutical R&D and oversees the discovery and commercialization of our programs, collaborations, and optimization of our technologies.